Analysis of Endocan Levels in Hypertensive Patients as Risk Factors of Chronic Kidney Disease
DOI:
https://doi.org/10.24293/ijcpml.v27i1.1571Keywords:
Endocan, endothelial dysfunction, hypertension, chronic kidney diseaseAbstract
This study aimed to analyze endocan levels as a marker of endothelial dysfunction in the control group, patients with stage I hypertension, stage II hypertension, and patients with end-stage renal disease. Endocan levels were measured with ESM-1 (endocan) kit by Enzyme-Linked Immunosorbent Assay (ELISA) method. This study used a cross-sectional method and was conducted in Dr. Wahidin Sudirohusodo Hospital, Makassar and Hasanuddin University Hospital from September to October 2017. There were 83 samples in this study, consisting of 12 samples in the control group, 22 samples of stage I hypertension, 28 samples of stage II hypertension, and 21 samples of end-stage renal disease aged 20-90 years old. This study showed significantly higher endocan levels in patients with stage II hypertension and end-stage renal disease (p< 0.05). Endocan levels were significantly higher (p<0.05) in patients with end-stage renal disease compared with the control group and patients with stage I hypertension; but not significantly higher (p > 0.05) compared to patients with stage II hypertension. Also, the median of endocan levels in patients with the end-stage renal disease was higher (309,850 ng/L) compared to patients with stage II hypertension (273,050 ng/L).
Downloads
References
JNC VII. The seventh report of the Joint National Committee on prevention, detection, evaluation, and
treatment of high blood pressure. JAMA, 2003; 289: 2560-71.
CDC. National chronic kidney disease fact sheet: General information and national estimates on chronic kidney disease in the United States. Atlanta: US Department of Health and Human Services. Centers for Disease Control and Prevention. 2014. Available at: http://www.cdc.gov/diabetes/pubs/factsheets/kidney.htm (accessed 15 February, 2017)
KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements, 2013; 3(1): 63-73.
Basic Health Research, Health Research and Development Agency Ministry of Health Republic of
Indonesia. 2013; 95-103.
Kali A, Shetty KSR. Endocan: A novel circulating proteoglycan. Indian J Pharmacol, 2012; 46 (6):
-583.
Kang YH, Ji NY, Han SR, Lee CI, Kim JW, et al. ESM-1 regulates cell growth and metastatic process through activation of NF- k B in colorectal cancer. Cell Signal, 2012; 24(10): 1940-9.
Afsar B, Takir M, Kostek O, Covic A, Kanbay M. Endocan: A new molecule playing a role in the
development of hypertension and chronic kidney disease. The Journal of Clinical Hypertension, 2014; 16
(12): 914-916.
Human ESM-1 (Endothelial Cell Specific Molecule 1) ELISA Kit. Available at: http://www.elabscience.com (accessed 2 April, 2017).
Bakri S, Lawrence GS. Genetics of hypertension. In: Lubis HR. Hypertension and kidney: In the framework of full service Prof. Dr. Harun Rasyid Lubis, Sp.PD-KGH. Field. USU Press, 2008; 19-31.
Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Kurtoglu E, et al. Endocan-a novel inflammatory
indicator in newly diagnosed patients with hypertension: A pilot study. Angiology, 2013; 1-5.
Campbell D, Weir MR. Defining, treating, and understanding chronic kidney disease-a complex
disorder. The Journal of Clinical Hypertension, 2015; 17(7): 514-27.
Chen J, Hamm LL, Mohler ER, Hudaihed A, Arora R, et al. Interrelationship of multiple endothelial
dysfunction biomarkers with chronic kidney disease. PLos One, 2015; 10(7): 1-10.
Glancy MR. Endocan as a potential diagnostic or prognostic biomarker for chronic kidney disease.
Kidney International, 2014; 86: 1079-81.
Kose M, Emet S, Akpinar TS, Kocaaga M, Cakmak R, et al. Serum endocan level and the severity of coronary artery disease: A pilot study. Angiology, 2015; 66(8):727-31.
Lee HG, Choi HY, Bae JS. Endocan as a potential diagnostic or prognostic biomarker for chronic kidney disease. Kidney International, 2014; 86: 1079-81.
Yilmaz MI, Siriopol D, Saglam M, Kurt YG, Unal HU, et al. Plasma endocan levels associate with
inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int, 2014; 86: 1213-20.
Rahmania L, Cortes DO, Irazabal M, Mendoza M, Santacruz C, et al. Elevated endocan levels are
associated with development of renal failure in ARDS patients. Intensive Care Med Exp, 2015; 3(1): A264.
Su YH, Shu KH, Hu CP, Cheng CH, Wu MJ, et al. Serum endocan correlated with stage of chronic kidney disease and deterioration in renal transplant recipients. Transplant Pro, 2014; 46(2): 323-7.
Whayne TF. Endocan in hypertension and cardiovascular disease. Angiology, 2016; 20: 1-3.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
